Literature DB >> 21679285

Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS).

M-Á Barba-Romero1, A Rivera-Gallego, G Pintos-Morell.   

Abstract

AIMS: Fabry disease (FD) is an X-chromosome-linked transmitted lysosomal storage disorder as a result of the deficient activity of enzyme α-galactosidase A. This leads to accumulation of neutral glycosphingolipids associated with organ involvement and premature death. We report the clinical characteristics of Spanish patients enrolled on the Fabry Outcome Survey (FOS; an international multicentre registry for the disease) and also compare these data with those from the rest of Europe.
METHODS: Baseline clinical data of 92 patients (41 males and 51 females) are described and analysed globally and according to gender. We compare the data of Spanish patients with those previously published from the rest of Europe patients in FOS.
RESULTS: Mean age of onset of symptoms in men was 20, and 24 years in women, with a mean delay of 11 years to the diagnosis in both genders. The predominant clinical involvement in male patients was renal (69%), cardiac (66%) and neurological (60%), and for female patients, it was neurological (42%), cardiac (33%), keratopathy (30%) and nephropathy (28%). Disease severity was significantly higher in male patients. Compared to the rest of European FOS-patients, Spanish patients were diagnosed at an earlier age with a smaller proportion of disease-related involvement for most organ irrespective of gender, though not its global severity in male patients.
CONCLUSIONS: We present the largest cohort of Spanish patients diagnosed with FD. The pattern of involvement (though not its global severity) could be different in Spanish patients in comparison with others from Europe. Expanding the knowledge of FD will permit early diagnosis as well as the possibility of starting the specific treatment.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21679285     DOI: 10.1111/j.1742-1241.2011.02695.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  7 in total

Review 1.  Quality of life in patients with Fabry disease: a systematic review of the literature.

Authors:  Maarten Arends; Carla E M Hollak; Marieke Biegstraaten
Journal:  Orphanet J Rare Dis       Date:  2015-06-16       Impact factor: 4.123

2.  Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.

Authors:  Miguel-Ángel Barba-Romero; Guillem Pintos-Morell
Journal:  Int J Mol Sci       Date:  2016-11-24       Impact factor: 5.923

Review 3.  Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.

Authors:  Regina El Dib; Huda Gomaa; Alberto Ortiz; Juan Politei; Anil Kapoor; Fellype Barreto
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240

4.  Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: A single-center study in Turkey.

Authors:  Hasan Ali Barman; Sevgi Özcan; Adem Atıcı; Caner Özgökçe; Ahmet Öztürk; Ayşegül Ezgi Kafalı; Nafiye Emel Çakar; Mustafa Emir Tavşanlı; Mehmet Küçük; Irfan Şahin; Ertuğrul Okuyan
Journal:  Anatol J Cardiol       Date:  2020-01       Impact factor: 1.596

5.  Fabry disease in the Spanish population: observational study with detection of 77 patients.

Authors:  Irene Vieitez; Olga Souto-Rodriguez; Lorena Fernandez-Mosquera; Beatriz San Millan; Susana Teijeira; Julian Fernandez-Martin; Felisa Martinez-Sanchez; Luis Jose Aldamiz-Echevarria; Monica Lopez-Rodriguez; Carmen Navarro; Saida Ortolano
Journal:  Orphanet J Rare Dis       Date:  2018-04-10       Impact factor: 4.123

Review 6.  Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review.

Authors:  Carlota Pascoal; Sandra Brasil; Rita Francisco; Dorinda Marques-da-Silva; Agnes Rafalko; Jaak Jaeken; Paula A Videira; Luísa Barros; Vanessa Dos Reis Ferreira
Journal:  Orphanet J Rare Dis       Date:  2018-11-28       Impact factor: 4.123

7.  Evaluating enzyme replacement therapies for Anderson-Fabry disease: commentary on a recent report.

Authors:  Roberto Giugliani; Stephanie Westwood; Hartmann Wellhoefer; Jörn Schenk; Andrey Gurevich; Christoph Kampmann
Journal:  Genet Mol Biol       Date:  2018-10-11       Impact factor: 1.771

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.